The FreeStyle Libre 2 continuous glucose monitor (CGM). [Image from Abbott] Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...
The new Libre app. [Image courtesy of Abbott] Abbott (NYSE:ABT) announced today that it entered a first-of-its-kind agreement to integrate data from its Libre systems into Epic EHR systems. The ...
ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology 1, today announced that it has entered a ...
ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology 1, today announced that it has entered a ...
ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology 1, today announced that it has entered a ...
Abbott Laboratories ABT presented late-breaking clinical data that demonstrate the FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor. The results were presented at the ...